Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Optimized Production, Quality Control, Biological Evaluation and Pet/Ct Imaging of 68Ga-Psma-617 in Breast Adenocarcinoma Model Publisher



Sharifi M2 ; Yousefnia H2 ; Bahramisamani A2 ; Jalilian AR1, 4 ; Zolghadri S2 ; Alirezapour B2 ; Geramifar P1 ; Maus S3 ; Beiki D1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14395-836, Iran
  3. 3. Clinic of Nuclear Medicine, University Medical Centre Mainz, Langenbeckstr. 1, Mainz, D-55131, Germany
  4. 4. Radioisotope Products and Radiation Technology Section, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, PO Box 100, Vienna, 1400, Austria

Source: Radiochimica Acta Published:2017


Abstract

Optimized production, quality control and preclinical evaluation of 68Ga-PSMA-617 as a PET radiotracer for PSMA-positive malignancies as well as successful application in imaging of breast adenocarcinomas are reported. 68Ga-PSMA-617 radiolabeling and QC optimization, stability, log P, biodistribution in breast adenocarcinomas-bearing mice (direct and blockade studies) and also PET/CT imaging was performed. 68Ga-PSMA-617 complex was prepared in high radiochemical purity (>96%, ITLC, HPLC) and specific activity of 300-310 GBq/mM at 95 °C using 2-4 micrograms of the peptide in 10 min followed by solid phase purification. The tracer was stable in serum and final formulation for at least 120 min. The log P was-1.98. Western blot test on the tumor cell homogenates demonstrated distinct existence of the PSMA on the surface. The biodistribution of the tracer demonstrated specific kidney and tumor significant uptake using blocking study. Significant tumor:blood and tumor:muscle ratio uptake observed at 30 min post-injection (2.69 and 19.1, respectively). A reduction of 40-80% off tumor uptake in the study time period observed using blocking test. 68Ga-PSMA-617 can be proposing a possible tracer for PET imaging of breast adenocarcinomas and other breast malignancies. © 2017 Walter de Gruyter GmbH, Berlin/Boston.